The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats

Sebastian Steven(Johannes Gutenberg University Mainz), Andreas Daiber(Johannes Gutenberg University Mainz)

Redox Biology

June 22, 2017

10.1016/j.redox.2017.06.009

Cited by 303

Related Papers

The Sodium-Glucose Co-Transporter 2 Inhibitor Empagliflozin Improves Diabetes-Induced Vascular Dysfunction in the Streptozotocin Diabetes Rat Model by Interfering with Oxidative Stress and Glucotoxicity

|PLoS ONE|2014|291

Ablation of lysozyme M-positive cells prevents aircraft noise-induced vascular damage without improving cerebral side effects

|Basic Research in Cardiology|2021|37